12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IDX719: Additional Phase IIa data

Idenix reported additional data from 64 treatment-naïve patients with HCV genotypes 1, 2, 3 or 4 infection evaluating IDX719 for 3 days in the placebo-controlled Phase IIa portion of a double-blind, U.S. Phase I/IIa trial. In 29 patients with HCV genotype 1a infection, mean maximum viral load reductions from baseline ranged from 3.2-3.6 log10 IU/mL across all doses of IDX719. In 5 patients with HCV genotype...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >